Research Compound Information

WOLVERINE: 10 mg/10 mg ($55)

Overview

Wolverine is an informal market name for a two-component blend pairing BPC-157 with TB-500. The rationale for combining them is that they act through different pathways, which is proposed to give more complete signaling for tissue repair.

In plain terms

The two peptides in it are each studied in tissue-repair research contexts. BPC-157 is a 15-amino-acid sequence originally identified within a protein found in gastric juice, studied in preclinical models of tissue repair without a definitively identified receptor. TB-500 is a synthetic fragment of thymosin β4, a naturally occurring protein whose primary known function is binding actin — the structural protein cells use to build their internal scaffolding and to move. It is worth noting plainly that controlled human data for either component individually is limited, and that combination products have not been characterized as combinations in the published literature at all.

Technical description

BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV, MW 1419.5) corresponding to residues 14–28 of human gastric juice protein BPC. No cognate receptor has been conclusively identified; reported preclinical activity has been attributed to VEGFR2–Akt–eNOS signaling and nitric oxide pathway modulation.

TB-500 is a synthetic peptide corresponding to the actin-binding domain of thymosin β4, commonly the fragment spanning residues 17–23 (LKKTETQ). Thymosin β4 is the principal G-actin sequestering protein in mammalian cells, and reported activity of the fragment concerns actin dynamics, cell migration, and angiogenesis in preclinical models. Pharmacokinetic and pharmacodynamic interaction between the two constituents has not been characterized in published literature.

Type: Two-component blend
Component 1: BPC-157 — 10 mg
Component 2: TB-500 (thymosin β4 fragment) — 10 mg
Total peptide mass: 20 mg
Appearance: White lyophilized powder
Storage: Lyophilized: −20 °C, protected from light. Reconstituted: 2–8 °C.

Blend composition must be confirmed. This name is an informal designation used in the research-chemical market rather than a standardized formulation, and stated composition varies between suppliers. The constituents described below reflect the most commonly cited formulation. Replace this section with your own verified composition and per-component masses, taken from your certificate of analysis, before publishing.

Trademark note. This name corresponds to a character trademarked by Marvel Characters, Inc. Using it as a commercial product designation carries trademark exposure independent of any other regulatory consideration. Recommend renaming before launch.

Regulatory status

Neither constituent is an FDA-approved drug or a lawful dietary supplement ingredient. BPC-157 was placed in Category 2 of the FDA's bulk drug substances review in 2023, identified as raising significant safety risks for use in compounding. Both constituents are prohibited by the World Anti-Doping Agency. No combination product containing these substances holds marketing authorization in any jurisdiction. Material supplied for laboratory research is not manufactured, tested, or released under pharmaceutical standards.

Research use only. This compound is described and supplied for laboratory research purposes exclusively. It is not a drug, dietary supplement, or cosmetic, and is not intended or approved for human or veterinary use, consumption, diagnosis, treatment, cure, or prevention of any disease. Not for internal or external use in humans or animals. The information above summarizes published scientific literature and is provided for reference; it is not guidance for use in any living subject.